Shots:

• The P-II (VLA15-221) trial evaluates VLA15 after administration of two or three primary series doses in 585 healthy patients aged 5-17yrs. with LD
• The results showed that patients treated with VLA15 in either a two-dose schedule or three-dose schedule were found to be more immunogenic compared to adults with both vaccination schedules tested & the safety profile was similar to prior reported data in adult patients
• The companies are expected to initiate a P-III trial to evaluate VLA15 in adults & pediatric patients aged ≥5yrs. in Q3’22, based on the P-II (VLA15-221) trial. The immunogenicity & safety data support a three-dose primary vaccination schedule in pediatric patients in the P-III study

Ref: Globenewswire | Image: Valneva